Minimal disease monitoring by QRT-PCR: Guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials

Journal of Pathology

Volumn 216, Issue 2, 2008, Pages 245-252

  Viprey, V F ^a,e   Lastowska, M A ^b   Corrias, M V ^c   Swerts, K ^d   Jackson, M S ^b   Burchill, S A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c G GASLINI INSTITUTE   (Italy)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bone marrow; Microarrays; Minimal residual disease; Neuroblastoma; Peripheral blood; Real time RT PCR

Indexed keywords

DOUBLECORTIN; MESSENGER RNA; MOLECULAR MARKER; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPRESSED SEQUENCE TAG; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOLECULAR PROBE; MONITORING; NERVE FUNCTION; NEUROBLASTOMA; PAIRED LIKE HOMEOBOX 2B GENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VALIDATION STUDY;

DNA PROBES; EXPRESSED SEQUENCE TAGS; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 53149137411     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2406     Document Type: Article

References (28)

1. Burchill SA. Micrometastases in neuroblastoma; are they clinically important? J Clin Path 2004;57:14-20.
2. Cheung IY, Feng Y, Vickers A, Gerald W, Cheung NV. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn 2007;9:237-241.
3. Swerts K, De Moerloose B, Dhooge C, Vansesompele J, Hoyoux C, Beiske K, et al. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells. Clin Chem 2006;52:438-445.
4. Cheung IY, Cheung NKV. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001;7:1698-1705.
5. Burchill SA, Bradbury FM, Selby P, Lewis IJ. Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Eur J Cancer 1995;31:553-556.
6. Miyajima Y, Horibe K, Fukuda M, Matsumoto K, Numata S, Mori H, et al. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1996;77:1214-1219.
7. Kuroda T, Saeki M, Nakano M, Mizutani S. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. J Pediatr Surg 1997;32:69-72.
8. Shono K, Tajiri T, Fujii Y, Suita S. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma. J Pediatr Surg 2000;35:1415-1420.
9. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma; a Children's Cancer Group Study. J Clin Oncol 2000;18:4067-4076.
10. Burchill SA, Lewis IJ, Abrams KR, Riley R, Imeson J, Pearson AD, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001;19:1795-1801.
11. Fukuda M, Miyajima Y, Miyashita Y, Horibe K. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma; a pilot study. J Pediatr Hematol Oncol 2001;23;10-13.
12. Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, et al. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 2001;36:203-204.
13. Riley RD. Money D. Jones OR. Sutton AJ. Lambert PC. Abrams KR. et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004;10:4-12.
14. Viprey VF. Corrias MV, Kadegal B. Oltra S. Swells K. Vicha A. et al. Slandardisation of operaling procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma; quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer 2007;43:341-350.
15. Brodeur GM. Pritchard J. Berthold F. Carlson NL. C'astel V. Castelberry RP. et al. Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
16. Lastowska M. Viprey V. Santibanez-Koref M. Wappler I, Peters H. Cullinane C. et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarruys with survival data. Oncogene 2007;26:7432-7444.
17. Burchill SA. Bradbury FM. Smith B. Lewis IJ. Selby P. Neuroblastoma cell detection by reverse transcriptase-polymoraso chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer 1994;57:671-675.
18. Oltra S, Martinez F. Orellana C. Cirau E. Fernandez JM. Canete A. et al. The doublecorlin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol 2005;14:53-57.
19. Cheung IY. Lo Piccolo MS. Kushner BH. Kramer K. Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction; clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003;21;1087-1093.
20. Cheung IY. Lo Piccolo MS. Collins N. Kushner BH. Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcription PCR; utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 31-8. Cancer 2002;94:3042-3048.
21. van der Velden VHJ. Hochhaus A, Cazzaniga G. Szczepanski T. Gabert J. van Dongen JJM. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-1034.
22. Chalifa-Caspi V. Yanai I. Ophir R. Rosen N. Shmoish M. Benjamin-Rodrig H. et al. GeneAnnot; comprehensive two-was linking between oligonueleotide array probe-sets and GeneCards genes. Bioinformatics 2004;20:1457- 1458.
23. Gautier L. Møller M. Friis-Hansen L. Knudsen S. Alternative mapping of probes lo genes for Affymetrix chips. BMC Bioinformatics 2004;5:111.
24. Harbig J. Sprinkle R. Enkemann SA. A sequence-based identification of the genes detected by probe-sets on the Affymetrix U133 plus 2.0 array. Nucleic Acids Res 2005;33:e31.
25. Ferrari F. Bortoluzzi S. Coppe A. Sirota A. Safran M. Shmoish M. et al. Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformaties 2007;8:446.
26. Lacroix JL. von Knebel Doeberitz M. Technical aspects of minimal residual disease detection in carcinoma patients. Semin Sura Oncol 2001;20:252-264.
27. Steinbach D. Schramm A. Eggert A. Onda M. Dawezynski K, Rump A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukaemia. Clin Cancer Res 2006;12:2434-2441.
28. Son CG, Bilke S. Davis S. Greer BT. Wei JS. Whiteford CC, et al. Database of mRNA gene expression profiles of multiple human organs. Genome Res 2005;15:443-450.